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ABSTRACT
The oligodendrocyte-myelin glycoprotein is a ligand of the
neuronal Nogo receptor and a potent inhibitor of neurite
outgrowth, but its physiological function remains to be elu-
cidated. The oligodendrocyte-myelin glycoprotein is
anchored solely in the outer leaflet of the plasma mem-
brane via its glycosylphosphatidylinositol anchor, and
through its leucine-rich repeat domain, it likely interacts
with other proteins. In the present study, we compare its
buoyancy and detergent solubility characteristics with
those of other myelin proteins. Based on its detergent solu-
bility profile and membrane fractionation using established
ultracentrifugation procedures, we conclude that the oligo-
dendrocyte-myelin glycoprotein is a lipid raft component
that is closely associated with the axolemma. Moreover, it
associates with caveolin-1 and caveolin-1-enriched mem-
branes. We postulate that, by virtue of its concentration in
lipid rafts and perhaps through interactions with caveolin-
1, the oligodendrocyte-myelin glycoprotein may influence
signaling pathways. VC 2005 Wiley-Liss, Inc.
INTRODUCTION
The oligodendrocyte (OLG)-myelin glycoprotein
(OMgp) was initially identified as a glycosylphosphatidy-
linositol (GPI)-linked peanut agglutinin (PNA)-binding
glycoprotein that appears relatively late in CNS develop-
ment (Mikol and Stefansson, 1988). While it is believed
to be myelin associated and paranodally localized (Mikol
et al., 1990b), its exact cell(s) of origin is unclear. The
structure of OMgp includes a highly conserved domain
of eight tandem leucine-rich repeats (LRRs) and a C-
terminal GPI anchor, both of which are likely to be of
functional significance (Mikol et al., 1990a,b, 1993). The
LRR domain is strongly implicated in mediating pro-
tein–protein interactions (Kobe and Deisenhofer, 1994,
1995), while the GPI lipid tail affords a high degree of
lateral mobility and may facilitate biological responses
through interactions with transmembrane signaling
molecules (Brown, 1993; Sharom and Lehto, 2002).
GPI-linked proteins are often concentrated in lipid
rafts in the vicinity of caveolae (Mayor et al., 1994;
Schnitzer et al., 1995; Liu et al., 1997; Fielding and
Fielding, 2003). Lipid rafts and caveolae are plasma
membrane microdomains that contain abundant choles-
terol, glycosphingolipids and signaling molecules, but
are distinguished by the fact that only caveolae are
enriched in caveolins (Lisanti et al., 1994b). Caveolins
are small hairpin-shaped molecules that provide the
structural backbone of caveolae vesicles (Lisanti et al.,
1993) and have diverse effects on signal transduction
(Okamoto et al., 1998). Caveolin-1 (Cav-1) [24 (a) kD
and 21 (b) kD isoforms], the most prevalent isoform,
binds to itself to form a multimeric complex (Fra et al.,
1995), serving as a scaffold for a variety of signaling
molecules (Sargiacomo et al., 1995). Whether a compo-
nent of lipid rafts or caveolae, GPI-linked proteins are
thought to modulate signaling pathways through signal-
ing complexes enriched in these membrane microdomains
(Abrami et al., 2001; Massimino et al., 2002; Fielding and
Fielding, 2003).
Myelin consists of a complex bioarchitecture that
includes compact lamellae and looser membrane struc-
tures such as periaxonal membranes and paranodal
loops (Trapp et al., 2004). While myelin serves an insu-
lative function, it is also physiologically active and in
close contact with the axons it ensheathes. In fact, rigor-
ous myelin subfractionation procedures demonstrate
copurification of myelin and axolemmal proteins, termed
the myelin–axolemmal complex, reflecting high-affinity
interactions (Menon et al., 2003). Within myelin, lipid
raft domains are likely to compartmentalize signal
transduction pathways that involve proteins such as
20,30-cyclic nucleotide 30-phosphodiesterase (CNP) and
myelin oligodendrocyte glycoprotein (MOG) (Kim and
Pfeiffer, 1999). Here we compare the detergent solubility
and membrane subfractionation profile of OMgp with
that of other myelin proteins. We show that OMgp is a
component of lipid rafts, in part colocalizes with and
interacts with Cav-1, and is a constituent of the myelin–
axolemmal complex, and we discuss implications for the
possible physiological function of OMgp and its proposed
function as an inhibitor of neurite growth (Kottis et al.,
2002; Wang et al., 2002).
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A mouse monoclonal antibody (mAb) and affinity-puri-
fied rabbit polyclonal antibody (pAb) against Cav-1 were
purchased from Transduction Laboratories (C37120 and
C13630, respectively; Lexington, KY). Rabbit anti-mye-
lin-associated glycoprotein (MAG) pAb and rat anti-mye-
lin basic protein (MBP) mAb were generous gifts from
Dr. J. Salzer (New York University, New York, NY), and
Dr. N. Groome (Oxford University, Headington, UK), re-
spectively. An anti-CNP mAb was purchased from Stern-
berger Monoclonals (SMI91; Lutherville, MD), while anti-
NG2 pAb was obtained from Chemicon International
(AB5320; Temecula, CA). Antibodies against voltage
gated sodium channels, Caspr-1, and potassium chan-
nels (Kv1.2) were kindly provided by Dr. M. Rasband
(University of Connecticut, Farmington, CT). Our rabbit
anti-OMgp pAb was previously described (Mikol and
Stefansson, 1988). In addition, we generated rabbit pAb
against a multiple antigenic peptide (Posnett and Tam,
1989) of OMgp (OMgp-pep) that is 100% conserved
between mouse (Mikol et al., 1993) and human (Mikol et al.,
1990b) (accession numbers Q63912 and X51694.1, respec-
tively). OMgp-pep (LLDKSDTAYQWNLKYLDVSKN, resi-
dues 89–109) was generated in the University of Michigan
Protein Structure Core Facility. Antigenicity analysis deter-
mined that OMgp-pep, contained within the LRR, was
likely to be the most immunogenic region within OMgp.
Antibodies against OMgp-pep were affinity-purified on an
agarose-OMgp-pep column that was prepared using Affi-
Gel 10 (Bio-Rad Laboratories, Hercules, CA).
Cell and Tissue Sources
Stripped adult rat brains or mouse brains were pur-
chased from Pel-Freez (Rogers, AR). The human oligo-
dendrocytic cell line M03.13 (McLaurin et al., 1995) was
generously provided by Dr. N. Cashman (University of
Toronto, Toronto, ONT, Canada). In general, cells were
grown at 37C in a humidified atmosphere with 10%
CO2. Before analysis, MO3.13 cells were grown to 80%
confluency.
Detergent Extractions, Myelin Preparation, and
Membrane Fractionation
Rat brains placed in phosphate-buffered saline (PBS;
0.05 g/ml) plus 1 mM phenylmethylsulfonylfluoride
(PMSF) and protease inhibitor cocktail (Boehringer-
Mannheim, Indianapolis, IN) with or without detergent
at 4C were disrupted using a Dounce homogenizer (6–8
strokes each loose pestle followed by tight pestle) and
centrifuged at 100,000g for 1 h. Supernatant and pellet
fractions were collected for analysis; the pellet fraction
was further homogenized separately in one of three
detergents: Triton X-100 (TX-100) at 1% (vol/vol), octyl-
glucopyranoside (OCTG) at 60 mM, and 3-[(3-cholamido-
propyl)dimethylammonio]-1-propane sulfonate (CHAPS)
at 30 mM. After centrifuging at 100,000g for 1 h, deter-
gent soluble and insoluble fractions were collected for
immunoblot analysis.
Compact myelin membranes were first prepared from
rat brain by the standard method of Norton and Poduslo
(1973) at 4C in the presence of 1 mM PMSF and pro-
tease inhibitor cocktail (Boehringer-Mannheim), and
fractions were collected at different stages in the isola-
tion procedure. In recent years, it has become apparent
that distinct myelin compartments exist, and it has
become possible to analyze myelin membranes in greater
detail. Thus, in separate experiments, more comprehen-
sive subfractions of mouse brain myelin were prepared
according to the procedure of Menon et al. (2003), with
all steps carried out at 4C. Here, P30 day-old mouse
brains were dissected and homogenized in 0.32 M
sucrose (5% w/v) using a Dounce homogenizer
(15 strokes), and homogenates (18 ml) were layered over
0.85 M sucrose (18 ml) in each of four 40-ml centrifuge
tubes, which were then centrifuged at 140,000g for 1 h
in a Beckman SW28 rotor. Thirteen fractions were col-
lected from gradient I: fraction 1 (6 ml), fractions 2–12
(2 ml each), fraction 13 (7 ml), and a pellet. Fractions
7–9 (light band) and fractions 10–13 (dispersed band)
were pooled and diluted with 10 mM EGTA in water at
pH 7.5. This sample was then homogenized (15 strokes)
and centrifuged at 200,000g for 20 min (Beckman Ti
50.2). Pellets were resuspended in 10 mM EGTA (pH
7.5), homogenized, stirred for 15 min and centrifuged at
35,000g for 15 min (Sorvall SS-34). This was repeated
once. The final pellets were resuspended in 18 ml
0.85 M sucrose and homogenized (15 strokes). A single
discontinuous sucrose gradient was prepared with 2 ml
1 M sucrose, 18 ml 0.85 M sucrose/homogenate, 18 ml
0.32 M sucrose and centrifuged at 140,000g for 90 min.
This constitutes gradient II.
Fourteen fractions were collected from gradient II:
fraction 1 (6 ml), fractions 2–12 (2 ml each), fraction 13
(8 ml), fraction 14 (3 ml), and a pellet. Fractions 8–9
(light density) and 10–13 (dispersed band) were com-
bined and diluted with 2 mM EGTA in water (pH 7.5),
homogenized (15 strokes), and centrifuged at 200,000g
for 20 min. Pellets were resuspended in 120 ml 2 mM
EGTA, homogenized (no stirring) and centrifuged at
35,000g for 15 min. Pellets were resuspended in 12 ml
0.85 M sucrose and homogenized. A single discontinuous
gradient was prepared with 12 ml 0.85 M sucrose/homo-
genate, 12 ml 0.75 M sucrose, 12 ml 0.32 M sucrose and
centrifuged at 140,000g for 16 h; 1-ml fractions were col-
lected and diluted with 2 vol of 2 mM EGTA (pH 7.5),
and membranes were collected by centrifugation at
35,000g for 15 min. Pellets were resuspended in 0.5 ml
of 50 mM Tris-HCl (pH 7.5) plus protease inhibitor cock-
tail. Protein concentration was determined using a Pro-
tein Assay kit (Bio-Rad Laboratories); fractions 1–8 had
very little detectable protein. Samples were pelleted by
centrifugation and solubilized in 50 mM Tris-HCl, 5%
sodium dodecyl sulfate (SDS), 4 M urea (pH 6.8), and
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then mixed with sample buffer (Laemmli, 1970), and
5 lg/well of protein (2.5 lg/well for CNP, MBP, Caspr-1)
was loaded without boiling on 5% or 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
gels for immunoblot analysis.
Caveolin-enriched membranes (CEMs) were prepared
from rat brain or MO3.13 cells by one of two discontinu-
ous density-gradient centrifugation methods, as pre-
viously described (Mikol et al., 1999). While both meth-
ods take advantage of the buoyancy of CEMs, one also
involves the use of nonionic detergent, given the deter-
gent insolubility of CEMs (Lisanti et al., 1995); the other
uses sonication without detergent (Song et al., 1996).
Using either method, CEMs fractionate near the 15–
25% sucrose interface (Mikol et al., 1999). Generally, the
detergent-free method is preferred, as use of detergents
can artifactually result in both the loss of protein asso-
ciation with CEMs, as well as the apparent concentra-
tion of other molecules, such as GPI-linked proteins
(Schnitzer et al., 1995; Liu et al., 1997). Briefly, 0.75 g
rat brain or two 150 mm plates of MO3.13 cells were
used per 12-ml centrifuge tube, whether the detergent-
based or detergent-free protocol was followed. In either
case, after saving an aliquot of the initial homogenate,
6 ml of lysate in 40% sucrose was placed in a 12-ml cen-
trifuge tube and overlaid sequentially with 2 ml each
25% sucrose, 15% sucrose, and 5% sucrose, then centri-
fuged at 200,000g for 18–20 h. After centrifugation, 12
equal-volume (1-ml) aliquots from the top to bottom of
the centrifuge tube were collected, as was the insoluble
pellet, for immunoblot analysis.
Immunoprecipitations, SDS-PAGE, and
Immunoblotting
For immunoblotting purposes, cell and tissue lysates
were generally solubilized with RIPA (20 mM Tris, 0.16
M NaCl, 1 mM EDTA, 1 mM EGTA, 1% TX-100, 1% Na
deoxycholate, 0.1% SDS, 1 mM Na3VO4 [pH 7.2]) 1 pro-
tease inhibitors. For immunoprecipitations, 60 mM
OCTG was used as the sole detergent, as this confers
greater solubility to Cav-1 and Cav-1-associated proteins
(Lisanti et al., 1995; Song et al., 1996). For immunopre-
cipitations, lysates were sonicated, centrifuged to re-
move particulates and insoluble membranes, and incu-
bated for 30 min with protein A/G PLUS-agarose (Santa
Cruz Biotechnology, Santa Cruz, CA). Soluble portions
were mixed end-over-end overnight at 4C with antibody
to the protein of interest or pre-immune sera, and
immune complexes were then precipitated with protein
A/G PLUS-agarose for 2 h. Brain lysates, MO3.13 cell
fractions, washed immunoprecipitates or pre-stained
molecular mass standards (Amersham Life Science,
Arlington Heights, IL) were electrophoretically sepa-
rated by SDS-PAGE, transferred at 100 V for 1 h onto
Protran nitrocellulose membranes (Schleicher and
Schuell, Keene, NH), and blocked overnight with 4%
bovine serum albumin (for mAbs) or 5% nonfat powdered
milk (for pAbs) in TBST (10 mM Tris-HCl, 150 mM
NaCl, 0.05% Tween-20). Membranes were incubated
with the primary antibody of interest in TBST over-
night, washed 33 10 min in TBST, incubated for 1 h
with horseradish peroxidase-conjugated secondary anti-
body (Santa Cruz Biotechnology), again washed exten-
sively, and finally visualized with enhanced chemilumi-
nescence (ECL) reagents (Amersham, Piscataway, NJ).
Parallel immunoblots were incubated in the absence of
primary antibody (conjugate controls), and positive and
negative control lysates were immunoblotted along with
test lysates in order to verify specific binding.
RESULTS
While OMgp, MAG, and MBP are all CNS myelin pro-
teins, they are differentially distributed in myelin mem-
brane fractions. As shown in Figure 1, using a standard
method of myelin membrane preparation from rat brain,
OMgp is much more enriched in the intermediate osmo-
tic shock fraction, which contains primarily loose myelin
membranes and myelin fragments, as well as mem-
branes from other cell types, as compared with the final
preparation, which contains predominantly compact
myelin membranes (Norton and Poduslo, 1973). By com-
parison, MBP is enriched in compact myelin and MAG
is found in both compartments to a roughly equal extent
as compared with the total brain homogenate. These bio-
chemical findings indicate that the three myelin proteins
are distributed preferentially in different membrane
domains.
OMgp, MAG, and MBP also differ in terms of their
buffer and detergent solubilities. OMgp, a GPI-linked
myelin protein, almost exclusively partitions in the
membrane fraction of rat brain (Fig. 2), in keeping with
earlier studies of human brain OMgp (Mikol and Ste-
fansson, 1988). A very small fraction of OMgp is soluble,
which presumably reflects protein released by endogen-
ous phosphatidylinositol-specific phospholipase-C. For
comparison purposes, Cav-1 was examined. It is insolu-
ble in buffer, consistent with its membrane structure.
MBP is also insoluble in buffer, reflecting its behavior as
an extrinsic protein tightly bound by ionic interactions
that require high ionic strength to disrupt (Smith and
Braun, 1988). A small amount of MAG is soluble in buf-
fer alone, is slightly smaller than full-length MAG, and
likely represents proteolytically released dMAG (Sato
et al., 1984). The 100,000g insoluble membrane pellet
was next separately homogenized in three nonionic
detergents: TX-100, OCTG, and CHAPS. OCTG and
CHAPS structurally resemble glycosphingolipids and
cholesterol, respectively, and have been found to solubi-
lize GPI-linked proteins better than many nonionic
detergents (Hooper and Turner, 1988). As shown in
Figure 2, OMgp remains insoluble in TX-100 despite the
fact that its buoyancy characteristics change in the pre-
sence of this detergent (see Fig. 6). OMgp is quite solu-
ble in OCTG, as previously noted (Kottis et al., 2002)
and, to a slightly lesser extent, in CHAPS. Of note,
OMgp TX-100 solubility increases when membranes are
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incubated at 37C, which is a feature of lipid raft mem-
branes (not shown) (Kim and Pfeiffer, 1999). By compar-
ison, MBP is at least equally soluble in TX-100 as in
OCTG or CHAPS. The detergent solubility characteris-
tics of MAG are similar to those of MBP, in that both
are roughly equally soluble in all three detergents,
although MAG is generally more detergent soluble. The
detergent solubility profile of Cav-1 is similar to that of
OMgp, with the exception that OMgp is more soluble in
CHAPS than is Cav-1. These findings support the view
that OMgp has solubility characteristics distinct from
MAG and MBP.
We then carried out more definitive experiments to
determine whether OMgp is contained within lipid raft
membranes of myelin, using established procedures that
begin with extraction of mouse myelin (Kim and Pfeiffer,
1999). First, rat brain myelin was centrifuged in sucrose
gradients after TX-100 extraction. Immunoblot analysis
of fractions shows that OMgp, like CNP, floats to the
lower density fractions of the sucrose gradient (Fig. 3A).
Purified mouse myelin was also extracted with TX-100
into insoluble and soluble fractions (Fig. 3B). As is the
case for CNP, a subpopulation of OMgp is insoluble in
TX-100. OMgp from purified myelin is relatively more
TX-100 soluble as compared with whole brain extraction
(see Fig. 2), which likely reflects the fact that more
manipulative steps have been carried out in first obtain-
ing myelin, and that the membrane environment of
Fig. 2. Buffer and detergent extracts of rat brain. Rat brain homo-
genate (H) was homogenized in buffer and centrifuged at 100,000gfor
1 h. Equal volume aliquots of the supernatant (S) and pellet (P) were
separated by SDS-PAGE. Very small fractions of oligodendrocyte
(OLG)-myelin glycoprotein (OMgp) (asterisk) and MAG (double aster-
isk) are soluble in buffer alone. The insoluble pellet was next homoge-
nized in either TX-100, OCTG, or CHAPS, and supernatants (S) and
pellets (P) of each were also separated by SDS-PAGE. Samples were
immunoblotted with anti-caveolin-1 (Cav-1), anti-OMgp, anti-MAG, or
anti-MBP. Cav-1 and OMgp have similar solubility characteristics: both
are largely insoluble in TX-100 and highly soluble in OCTG, while
OMgp is slightly more soluble in CHAPS. MAG and MBP appear
roughly equally soluble in all three detergents. Of note, MBP isoforms
are not separated on this 5% acrylamide gel, such that MBP appears as
a single band.
Fig. 1. Myelin protein enrichment within various membrane com-
partments from rat brain. Equal-volume aliquots of rat brain homoge-
nate, purified myelin from rat brain or the osmotic shock fraction from
a myelin preparation were immunoblotted with anti- oligodendrocyte
(OLG)-myelin glycoprotein (OMgp), anti-MBP, and anti-MAG. OMgp is
not enriched in the compact myelin fraction, whereas MBP and MAG
are. OMgp is relatively enriched in the osmotic shock fraction, which
contains looser myelin membranes, myelin fragments and membranes
derived from other neural cells. These results emphasize that the three
myelin proteins are contained within different membrane domains.
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OMgp in isolated myelin differs somewhat from that in
whole brain. In any case, the solubility pattern seen
here for both OMgp and CNP is similar to that observed
by Kim and Pfeiffer for CNP (1999). Finally, pretreat-
ment of purified myelin with 0.2% saponin at 4C, fol-
lowed by centrifugation, generated an insoluble fraction
that was further extracted with TX-100 at 4C and cen-
trifuged to yield a detergent soluble supernatant (S2)
containing both OMgp and CNP, and a pellet (P2) par-
tially depleted of OMgp and CNP. This latter observa-
tion is in accord with the report of Kim and Pfeiffer
(1999), except that in our hands, using mouse myelin,
the depletion of OMgp and CNP was not as complete as
from rat myelin. Thus OMgp is associated with deter-
gent-insoluble, glycosphingolipid/cholesterol-enriched micro-
domains (DIGCEM) and is a raft-associated protein.
We sought to dissect the membrane localization of
OMgp further by preparing fractions according to
Menon et al. (2003). We included in our marker profile
Cav-1 and NG2, the latter being a proteoglycan
expressed by glial progenitor cells (Chang et al., 2000;
Dawson et al., 2003; Aguirre et al., 2004). In the absence
of quantification data for individual proteins, it is still
possible to interpret the profile visually by comparing
band intensities amongst fractions, given that each lane
represents a constant amount of protein taken from the
fractions. As shown in Figure 4, OMgp is present to
some extent in every subfraction of the myelin prepara-
tion, but it is relatively most abundant in the pellet,
which is enriched in Caspr-1 and sodium and potassium
channels. These results reinforce those of Menon et al.
(2003), in that axolemmal components are retained in
purified ‘‘myelin’’ and demonstrate that OMgp is a com-
ponent of the myelin–axolemmal complex, or possibly
of OMgp-associated membranes that adhere to this
complex. Likewise, NG2-associated membranes bind to
myelin–axolemmal components, an observation not pre-
viously noted. As for OMgp and the sodium channel,
NG2 is more concentrated in the very dense and pellet
fractions.
To investigate partitioning of OMgp in Cav-1-enriched
membranes, CEMs were prepared from rat brain using
either the TX-100 (Fig. 5A) or detergent-free sodium car-
bonate method (Fig. 5B), or from MO3.13 cells using the
sodium carbonate method (Fig. 5C), as detailed in the
Methods. Using either method, buoyant CEMs partition
near the 15%/25% sucrose interface (Lisanti et al., 1995;
Song et al., 1996). OMgp is highly enriched within rat
brain CEMs prepared by the TX-100 method, which in
part might reflect artifactual partitioning of a GPI-linked
Fig. 3. Identification of oligodendrocyte (OLG)-myelin glycoprotein
(OMgp) as a DIGCEM-associated protein. A: Total rat brain myelin was
floated in sucrose gradients after TX-100 extraction at 4C. Nine frac-
tions and pellet were collected and immunoblotted for OMgp and CNP.
Immunoblot analysis shows that OMgp, like CNP, a DIGCEM-asso-
ciated protein, floats to the lower-density fractions (4–6) in the sucrose
gradient. B: Purified mouse myelin was extracted with TX-100 at 4C
and centrifuged to separate into detergent insoluble pellet (P) and
detergent soluble supernatant (S) fractions. As for CNP, a certain per-
centage of OMgp is found to be insoluble in TX-100. Pretreatment of
purified myelin with 0.2% saponin at 4C followed by centrifugation
separated a soluble fraction S1 from an insoluble fraction that was
further extracted with TX-100 at 4C and centrifuged into detergent-
soluble supernatant S2 and insoluble pellet (P2). Both OMgp and CNP
are found in supernatant S2, a requirement of DIGCEM-associated pro-
teins.
Fig. 4. Subfractionation of mouse myelin membranes. Mouse brain
myelin was subfractionated as described in Materials and Methods. Oli-
godendrocyte (OLG)-myelin glycoprotein (OMgp) is detected in every
subfraction of the ‘‘myelin’’ preparation, but is relatively enriched (lar-
gest band) in the pellet at the bottom of the gradient, which is enriched
in axolemma elements. Protein content is recorded in the protein profile
of the gradient. These data are a typical set taken from four indepen-
dent experiments.
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protein within lipid rafts in the presence of TX-100
(Schnitzer et al., 1995). Using the detergent-free method
of CEM preparation, OMgp is largely in fractions 7–12
(40% sucrose layer), although a smaller fraction is clearly
contained within CEMs (Fig. 5, lanes 4, 5, and 6). These
data show that a subpopulation of OMgp associates with
membranes enriched in Cav-1 and suggest indirectly that
OMgp is highly mobile, given that its average buoyancy
differs considerably in the presence/absence of detergents.
We speculate that localization of OMgp in Cav-1-enriched
and nonenriched lipid raft domains is dynamic and
changes in response to as yet unknown biological trig-
gers. It is well recognized that protein association with
Cav-1-enriched domains may be a dynamic process
(Mineo et al., 1999; Chapman et al., 1999).
The human OLG-related cell line M03.13 expresses
OMgp and other myelin proteins such as MBP
(McLaurin et al., 1995) but does not make myelin. As
shown in Figure 5C, OMgp is enriched within CEMs of
MO3.13 cells using the detergent-free method. Here
Cav-1 appears as a doublet due to the higher gel concen-
tration (15% acrylamide); when using lower concentra-
tions (<10% acrylamide), Cav-1 is generally seen as a
single band (Mikol et al., 2002). The above results indi-
cate that OMgp associates with Cav-1-enriched mem-
branes, but does not imply direct or indirect interactions
between the two proteins. Using MO3.13 cell lysates
and brain homogenates, we show that OMgp co-immu-
noprecipitates with Cav-1 (Fig. 6). Given that both Cav-
1 and OMgp are highly soluble in OCTG, this detergent
was utilized for immunoprecipitations. This association
with Cav-1 is likely to be indirect in view of the ancho-
rage of Omgp in the outer leaflet of the plasma mem-
brane and suggests that OMgp associates with the Cav-
1 complex through intermediary proteins or lipids.
DISCUSSION
Glycosphingolipids, cholesterol, and GPI-linked pro-
teins cluster together in distinct domains of the outer
leaflet of the plasma membrane, termed lipid rafts, in
which specific proteins are included while others are
excluded. Lipid rafts are characterized by insolubility in
certain detergents such as TX-100 at 4C (Schroeder
et al., 1994; Ahmed et al., 1997), and it is now clear that
such microdomains exist in living cells (Kurzchalia and
Parton, 1999), including OLGs (Taylor et al., 2002),
where their functions are thought to include concen-
Fig. 5. Oligodendrocyte (OLG)-myelin glycoprotein (OMgp) is con-
tained within caveolin-enriched membranes (CEMs) from rat brain or
MO3.13 cells. CEMs were prepared from rat brain by either the TX-100
(A) or detergent-free (B) methods (fractions 1, 2: 5% sucrose; fractions
3, 4: 15% sucrose; fractions 5, 6: 25% sucrose; fractions 7–12: 40%
sucrose). As shown in A, OMgp and caveolin-1 (Cav-1) are enriched in
CEMs using the TX-100 method. Using the detergent-free method, the
bulk of Cav-1 and a fraction of OMgp are detected in CEMs near the
15%/25% sucrose gradient (B). OMgp appears to be more buoyant in
the presence of TX-100, but nonetheless a fraction of OMgp is contained
within detergent-free CEMs, as shown by its presence in fractions 4–6.
Using the detergent-free method of preparing CEMs, OMgp is highly
enriched in CEMs from MO3.13 human oligodendrocytic cells (C).
OMgp, as detected by anti-OMgp-pep, is present in the same fractions
as Cav-1. On this high percentage (15%) acrylamide gel, Cav-1 sepa-
rates into its two isoforms, 24 kD (a) and 21 kD (b).
Fig. 6. Oligodendrocyte (OLG)-myelin glycoprotein (OMgp) and
caveolin-1 (Cav-1) co-immunoprecipitate. Human brain, rat brain or
MO3.13 lysates (100 lg each), or lysates (500 lg each) first immunopre-
cipitated (i.p.) with anti-Cav-1 pAb or preimmune serum, were immu-
noblotted with anti-OMgp-pep and the total i.p. analyzed. As shown,
OMgp is immunoprecipitated with Cav-1 but not with rabbit pre-
immune serum. The lysates serve as positive controls for OMgp immu-
noblotting. These results were reproduced in four separate experi-
ments.
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tration of signaling complexes and protein trafficking
(Simons and Wandinger-Ness, 1990; Brown and London,
1998; Simons and Toomre, 2000). Our findings support
the view that OMgp exists in a unique lipid raft envi-
ronment.
Fractionation of OMgp during myelin purification and
detergent solubility profile differ from two other myelin
proteins, MAG and MBP (Figs. 1 and 2). Moreover,
using several criteria, OMgp is found in DIGCEM or
lipid rafts (Figs. 3 and 4). Although we have not used
their full complement of membrane markers, we have
reproduced the observations of Menon et al. (2003)
regarding the myelin and axolemmal proteins that are
normally present in conventional mouse myelin prepara-
tions, for which ‘‘myelin purity’’ is often assumed. OMgp
is present to some extent in every subfraction of the pre-
paration, but it is relatively abundant in the pellet at
the bottom of the gradient, where the total protein con-
tent comprises 25% of the protein applied to this gradi-
ent. In other words, a significant amount of OMgp is
associated with membrane elements that are relatively
depleted of the myelin proteins MBP and CNP but
enriched in elements of the axolemma (voltage-gated
sodium channels; Caspr-1; potassium channels).
Given the paucity of lamellar myelin components in
the pellet, these findings indicate that OMgp is either
present in the axolemma or in membrane elements of
oligodendroglial origin that remain tightly associated
with the axolemma, consistent with the observations of
Menon et al. (2003), or both. The cellular origin(s) of
OMgp are ambiguous. OMgp was originally named for
its expression by OLGs and concentration within myelin
membranes (Mikol and Stefansson, 1988; Habib et al.,
1998b). It may be expressed to some extent by neurons
as well (Habib et al., 1998b), but we have been unable
to detect it in cultured neurons (mouse cerebellar gran-
ule cells, anterior horn cells; P.E. Braun and D.D. Mikol,
unpublished observations). Further work is needed to
clarify the degree of OMgp expression by different
neural populations, particularly during development, as
pointed out in a recent review on OMgp (Vourc’h and
Andres, 2004).
Enrichment of Cav-1 in the pellet of the myelin sub-
fractionation procedure (Fig. 4), a component of specia-
lized membrane domains related to ‘‘lipid rafts,’’ is con-
cordant with our data showing that OMgp associates
with caveolar and lipid raft membranes. OMgp is found
in all subfractions, but is enriched where the ‘‘lightest’’
myelin elements occur (fractions 9–14) with the lowest
protein content, and where there is the lowest abun-
dance of (1) Na1 channels; (2) K1 channels; and (3) Cav-
1. This may reflect the presence of OMgp in membranes
that are not part of the myelin organelle, but that
adhere to it. NG2 is not a protein of myelinating OLGs,
but rather of glial progenitor cells, and it does not
appear to associate as well with lamellar myelin compo-
nents as with membranes in the pellet. The finding of
Cav-1 in the myelin–axolemmal complex is not surpris-
ing, in that Cav-1 is known to regulate diverse signaling
molecules. It is likely that Cav-1 is localized in part to
the paranodal membranes, which is in keeping with our
findings from peripheral nerve myelin (Mikol et al.,
1999).
Cav-1 has previously been identified in cultured OLGs
and myelin sheets (Arvanitis et al., 2004). Using either
method of CEM preparation, Cav-1 and OMgp are con-
tained in buoyant membranes from rat brain and
MO3.13 cells (Fig. 5). CEMs share many of the features
of caveolae (Lisanti et al., 1995; Song et al., 1996),
including enrichment in caveolin, cholesterol, glyco-
sphingolipids, and a variety of signal-transducing com-
ponents (Sargiacomo et al., 1993; Lisanti et al., 1994b).
Caveolae do not equate with lipid rafts, but can be con-
sidered a subset of them (Hooper, 1999; Kurzchalia and
Parton, 1999; Fielding and Fielding, 2003). In the pres-
ence of caveolin, these membrane domains can invagi-
nate to form uniformly sized (50–100-nM) vesicles (Oka-
moto et al., 1998). A ‘‘caveolae signaling hypothesis’’ pro-
poses that compartmentalization of signaling molecules
within caveolae allows for efficient coupling of activated
receptors to a number of different effector systems (Sar-
giacomo et al., 1993; Lisanti et al., 1994a; Okamoto
et al., 1998). These data support the view that, within
the OLG membrane, OMgp exists in an environment
rich in signaling complexes.
OMgp is present in CEMs and does, at least in part,
co-immunoprecipitate with Cav-1 from MO3.13 cells
(Fig. 6). Interestingly, using the detergent-free method,
OMgp is more enriched in CEMs from MO3.13 cells
than rat brain. We hypothesize that OMgp is closely
associated with OLG lipid rafts, but that its association
with Cav-1-enriched membranes might vary depending
upon a variety of factors, including degree of Cav-1
expression, cellular metabolic state, level of differentia-
tion, and degree of OMgp clustering (through interac-
tions with other molecules). We have previously shown
that Cav-1 expression by Schwann cells increases during
development and decreases following nerve transection
(Mikol et al., 1999, 2002), which is consistent with find-
ings in non-neural cell types that Cav-1 expression
increases during cellular differentiation and decreases
upon dedifferentiation (Fan et al., 1983; Scherer et al.,
1995; Koleske et al., 1995; Lee et al., 1998). It is also
possible that the lipid raft environment differs in imma-
ture, nonmyelinating vs. differentiated, myelinating
OLGs. Our observation that a subpopulation of OMgp is
contained in lipid rafts is in keeping with data showing
that 40% of CNP and MOG are associated with lipid
rafts (Kim and Pfeiffer, 1999). It is hypothesized that
the content of lipid rafts is dynamic, reflecting the acti-
vation/inactivation of various signaling pathways. The
concentration of at least several proteins has been
shown to fluctuate within lipid rafts or caveolae,
depending upon cellular physiological state or presence/
absence of cross-linking (Mineo et al., 1999; Muller
et al., 2002; Marta et al., 2003).
The physiological role of OMgp remains largely
unknown. One proposed function is a growth suppressive
effect (Habib et al., 1998a), and recently, the LRRs of
OMgp have been shown to be important for mediating this
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property (Vourc’h et al., 2003). This finding is of interest,
as the tumor suppressor protein neurofibromin is also
growth suppressive (Johnson et al., 1994). The OMgp
gene is contained within a large intron of the neurofibro-
matosis I gene (Viskochil et al., 1991) that encodes neu-
rofibromin, and it has been suggested that this complex
genetic arrangement may have evolved to enable coordi-
nated expression of two proteins that influence related
signaling pathways (Habib et al., 1998a). While the sig-
naling components affected by OMgp have not been fully
elucidated, our preliminary results show that OMgp and
neurofibromin regulate similar signaling pathways such
as mitogen-activated protein kinase and focal adhesion
kinase, and transfection of OMgp into NIH-3T3 cells
results in tyrosine phosphorylation of neurofibromin
(M. Boyanapalli and D.D. Miko unpublished observa-
tions). OMgp has also been shown to be a potent inhibi-
tor of neurite outgrowth (Kottis et al., 2002; Wang et al.,
2002). Whether this has physiological relevance remains
uncertain, although OMgp might possibly inhibit neuro-
nal sprouting at the paranode, where OMgp appears to
be localized (Mikol et al., 1999). OMgp is expressed rela-
tively late in development, and its recently identified
inhibitory effects on neurite outgrowth might simply
represent extension of a physiological role in inhibiting
sprouting of myelinated axons.
Given its ectomembrane structure, OMgp might inter-
act with other molecules (Mikol et al., 1990b). Of note,
co-immunoprecipitation of Omgp with Cav-1 (Fig. 6)
likely reflects the presence of an as yet unidentified
intermediary molecule, as OMgp is GPI-linked. Through
its LRR or perhaps some other domain, it is possible
that OMgp binds to (1) diffusible or matrix proteins, (2)
protein(s) on other cells, or (3) protein(s) on the same
cell. The latter is necessary if OMgp is involved in signal
transduction pathways. GPI-linked proteins are thought
to be present within lipid rafts in the vicinity of caveolin
domains, and upon ligand binding, might become
sequestered into caveolin-associated membrane domains
(Kasahara and Sanai, 2000). Further, cross-linking of
GPI-anchored proteins has been shown to activate sig-
naling pathways, such as those involving src-family
kinases (Brown, 1993; Mayor et al., 1994; Kasahara and
Sanai, 2000). It is conceivable that, consequent to pro-
tein–protein interactions, OMgp becomes clustered, trig-
gering signaling events within the OLG. At present, the
only protein with which OMgp is known to interact is
the Nogo receptor, a GPI-linked protein with LRRs that
is expressed by neurons (Wang et al., 2002). It is
unknown whether Nogo receptor binding induces clus-
tering of OMgp.
OMgp is almost entirely membrane-associated, reflect-
ing its GPI attachment. However, through the activation
of an endogenous phospholipase, which might occur, for
example, consequent to immune activation (Locati et al.,
2001), OMgp could be released as a soluble form. Of the
other identified neurite growth inhibitors, both MAG
and the Nogo receptor might also be solubilized, the
Nogo receptor via phospholipase, and MAG through pro-
teolytic action. There is, in fact, some evidence for the
latter (Sato et al., 1984). We hypothesize that mem-
brane-associated OMgp, Nogo receptor and MAG might
be focally released in certain disease states, particularly
those associated with inflammation, such as multiple
sclerosis. Soluble forms of these proteins might then
have paracrine effects, resulting in inhibition of axonal
regrowth.
In summary, we show that OMgp is a component of
lipid rafts and in part associates with Cav-1, and that
both are components of the myelin–axolemmal complex.
We speculate that OMgp is a GPI-linked neural protein
that interacts with Cav-1 and other unidentified mem-
brane proteins and modulates signaling pathways at the
myelin–axolemmal interface. Ongoing studies will fur-
ther explore signaling pathways involving OMgp and
the neural cell types affected.
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